Previous Close | 58.46 |
Open | 40.28 |
Bid | 39.20 x 800 |
Ask | 39.69 x 800 |
Day's Range | 32.96 - 40.51 |
52 Week Range | 32.96 - 195.99 |
Volume | |
Avg. Volume | 887,217 |
Market Cap | 2.211B |
Beta (5Y Monthly) | 1.61 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -11.96 |
Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 137.33 |
Subscribe to Yahoo Finance Plus to view Fair Value for MRTX
Mirati is unlikely to carve out a share of the lung cancer market, analysts said Friday as MRTX stock collapsed on a testing disappointment.
Mirati (MRTX) posts positive data from a phase II study evaluating its lung cancer candidate adagrasib. However, the drug caused side-effects in a large number of study participants.
The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week’s American Society of Clinical Oncology annual meeting. Arcellx Inc.’s (ACLX) stock jumped 11.9% after an abstract provided updated data for its CART-ddBCMA. SVB Securities analysts said in a note on Friday that they were pleased to see that the experimental therapy “continues to have a competitive efficacy signal in 24 evaluable relapsed/refractory patients.”